OncoVerity, Inc.
OncoVerity is a mission-driven biotechnology company dedicated to applying computational tools to clinical and biological data to develop therapies that improve outcomes for cancer patients. The company emphasizes innovation, collaboration, and a unique approach to cancer treatment, aiming to transform hope into reality for patients through advanced bioinformatics and multi-omics platforms.
Industries
Nr. of Employees
small (1-50)
OncoVerity, Inc.
OncoVerity is part of the Fitzsimons Innovation Community in Denver.
Products
Anti-CD70 monoclonal antibody program (licensed clinical-stage candidate)
A clinical-stage monoclonal antibody program directed at CD70 being developed for acute myeloid leukemia and other oncology indications; being advanced in combination trials with hypomethylating agents and BCL-2 inhibitor regimens in elderly newly diagnosed AML.
Anti-CD70 monoclonal antibody program (licensed clinical-stage candidate)
A clinical-stage monoclonal antibody program directed at CD70 being developed for acute myeloid leukemia and other oncology indications; being advanced in combination trials with hypomethylating agents and BCL-2 inhibitor regimens in elderly newly diagnosed AML.
Services
Identification of novel therapeutic targets in oncology using multi-omics data and computational analysis.
End-to-end early- to mid-stage oncology clinical trial execution including protocol management, enrollment and interim efficacy/safety reporting.
Regulatory planning and preparation for IND/IDE and related regulatory interactions, and oversight of regulatory labeling and promotional review.
Design and management of clinical supply operations including forecasting, sourcing, logistics and implementation of serialization/track-and-trace systems across markets.
Oversight of global quality systems, supplier management and support for product launch readiness including roles aligned with qualified/responsible person responsibilities.
Development and management of patient advocacy, stakeholder engagement, medical information and medical communications to incorporate the patient perspective into development.
Identification of novel therapeutic targets in oncology using multi-omics data and computational analysis.
End-to-end early- to mid-stage oncology clinical trial execution including protocol management, enrollment and interim efficacy/safety reporting.
Regulatory planning and preparation for IND/IDE and related regulatory interactions, and oversight of regulatory labeling and promotional review.
Design and management of clinical supply operations including forecasting, sourcing, logistics and implementation of serialization/track-and-trace systems across markets.
Oversight of global quality systems, supplier management and support for product launch readiness including roles aligned with qualified/responsible person responsibilities.
Development and management of patient advocacy, stakeholder engagement, medical information and medical communications to incorporate the patient perspective into development.
Expertise Areas
- Clinical trial management
- Multi-omics bioinformatics and target discovery
- Single-cell multi-omics
- Regulatory strategy and submissions (IND/NDA/BLA types)
Key Technologies
- Multi-omics analysis
- Single-cell multi-omics
- Bioinformatics and computational analysis for target identification
- Clinical trial data management and reporting
News & Updates
November 21, 2024: OncoVerity announced securing an extended Series A funding round to support the advancement of Cusatuzumab in newly diagnosed AML.
November 25, 2023: Study on Cusatuzumab plus azacitidine in Japanese patients with AML.
April 2, 2023: Research on the interaction between nasopharyngeal carcinoma cells and regulatory T cells.
March 2023: Announcement of licensing rights and leadership appointment.
August 2021: Clinical trial results on cusatuzumab combined with azacitidine.
September 2020: Study on cusatuzumab in nasopharyngeal carcinoma.
November 21, 2024: OncoVerity announced securing an extended Series A funding round to support the advancement of Cusatuzumab in newly diagnosed AML.
November 25, 2023: Study on Cusatuzumab plus azacitidine in Japanese patients with AML.
April 2, 2023: Research on the interaction between nasopharyngeal carcinoma cells and regulatory T cells.
March 2023: Announcement of licensing rights and leadership appointment.
August 2021: Clinical trial results on cusatuzumab combined with azacitidine.
September 2020: Study on cusatuzumab in nasopharyngeal carcinoma.